Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients.

Matteo Megna Elisa CamelaTeresa BattistaLucia GencoFabrizio MartoraMatteo NotoVincenzo PiconeRuggiero AngeloGiuseppe MonfrecolaGabriella Fabbrocini Luca Potestio

Published in: Expert opinion on drug safety (2023)

Our review based on currently available evidence suggests biologics and OSM as an ideal treatment option for pediatric patients, with an excellent profile in term of efficacy and safety as compared to traditional systemic drugs.

Keyphrases

preterm infants
gestational age
atopic dermatitis
replacement therapy
childhood cancer
preterm birth